Literature DB >> 9360930

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

V Lacronique1, A Boureux, V D Valle, H Poirel, C T Quang, M Mauchauffé, C Berthou, M Lessard, R Berger, J Ghysdael, O A Bernard.   

Abstract

The Janus family of tyrosine kinases (JAK) plays an essential role in development and in coupling cytokine receptors to downstream intracellular signaling events. A t(9;12)(p24;p13) chromosomal translocation in a T cell childhood acute lymphoblastic leukemia patient was characterized and shown to fuse the 3' portion of JAK2 to the 5' region of TEL, a gene encoding a member of the ETS transcription factor family. The TEL-JAK2 fusion protein includes the catalytic domain of JAK2 and the TEL-specific oligomerization domain. TEL-induced oligomerization of TEL-JAK2 resulted in the constitutive activation of its tyrosine kinase activity and conferred cytokine-independent proliferation to the interleukin-3-dependent Ba/F3 hematopoietic cell line.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9360930     DOI： 10.1126/science.278.5341.1309

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  214 in total

1.  Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.

Authors:  R Fenrick; J M Amann; B Lutterbach; L Wang; J J Westendorf; J R Downing; S W Hiebert
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Authors:  P Saharinen; K Takaluoma; O Silvennoinen
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 3.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components.

Authors:  L Van Rompaey; W Dou; A Buijs; G Grosveld
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

5.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

6.  Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

Authors:  Daniela Ungureanu; Pipsa Saharinen; Ilkka Junttila; Douglas J Hilton; Olli Silvennoinen
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

7.  Activated Fes protein tyrosine kinase induces terminal macrophage differentiation of myeloid progenitors (U937 cells) and activation of the transcription factor PU.1.

Authors:  Jynho Kim; Ricardo A Feldman
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

8.  Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.

Authors:  C A Kim; M L Phillips; W Kim; M Gingery; H H Tran; M A Robinson; S Faham; J U Bowie
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 9.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

10.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.